MedTrace Logo

Evaluation of the Clinical and Economic Impact of painPRIMER in the Treatment of Low Back Pain in a Primary Care Setting

NCT01838057 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 103

Last updated 2015-04-16

No results posted yet for this study

Summary

To evaluate the impact of painPRIMER in a prospective six-month clinical investigation looking at clinical outcomes, health care professional and patient satisfaction, healthcare resource use, productivity and direct and indirect costs. The hypothesis is that early identification of the presence of neuropathic pain and back pain related comorbidities, to direct appropriate pharmacologic and non-pharmacologic treatment, painPRIMER would improve patient outcomes and reduce patient cycling, inappropriate use of imaging and surgery, thereby reducing costs and productivity loss associated with these inefficiencies.

Conditions

  • Low Back Pain

Interventions

DEVICE

painPREMIER cohort

Low back pain patients prospectively recruited during the study period and managed with painPREMIER.

OTHER

Control cohort

A matched group of low back pain patients not managed with painPREMIER.

Sponsors & Collaborators

  • Piedmont Healthcare System

    collaborator UNKNOWN

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01838057 on ClinicalTrials.gov